Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Improving Opioid Use for Cancer Pain Framework: Addressing the needs of patients with cancer and pain in a new era of opioid prescribing.

Cancer·2026
Same author

Does the Edmonton Symptom Assessment Scale rule in or rule out anxiety and depression?

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

MASCC score and neutropenic complications: what is the likelihood?

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Intensive nursing intervention: what is the post treatment effect size on anxiety and depression?

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Caruso and psychotropic drug interactions with anticancer treatments.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Methodological considerations and biological context.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same journal

Growing the Next Generation of Hospice and Palliative Medicine Researchers.

Journal of pain and symptom management·2026
Same journal

Topical Amitriptyline, Ketamine, and Lidocaine Cream for Neuropathic Pain Control in Pediatric Oncology Patients.

Journal of pain and symptom management·2026
Same journal

Perceived Stigma, Psychological Distress, and Symptom Burden in Decompensated Cirrhosis.

Journal of pain and symptom management·2026
Same journal

Why We Should Rarely Override Surrogates.

Journal of pain and symptom management·2026
Same journal

Screening for Distress and Sources of Distress in Parents with Advanced Cancer and their Coparents.

Journal of pain and symptom management·2026
Same journal

Minimal Comfort Feeding in Advanced Dementia: Attitudes of Hospice and Palliative Care Professionals.

Journal of pain and symptom management·2026
See all related articles
  1. Home
  3. Routine Urine Drug Screening In Palliative Care - A Call For Evidence Before Implementation.
  1. Home
  3. Routine Urine Drug Screening In Palliative Care - A Call For Evidence Before Implementation.

Related Experiment Video

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

Routine Urine Drug Screening in Palliative Care - A Call for Evidence Before Implementation.

Mellar P Davis1, Katie Fitzgerald Jones2

  • 1Section Chief, Oncology Palliative Medicine, Department of Supportive Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

Journal of Pain and Symptom Management
|June 26, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

Routine urine drug screening (UDS) in palliative care lacks proven patient safety benefits and carries risks. Recommendations should be individualized pending evidence of benefit.

Keywords:
cancer painevidence-based medicinehealth equityopioid stewardshippalliative careracial disparitiesurine drug screeningurine drug testing

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Experiment Videos

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
10:17

High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry

Published on: April 23, 2019

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Area of Science:

  • Palliative Care
  • Pain Management
  • Medical Ethics

Background:

  • Urine drug screening (UDS) is increasingly used in palliative care for opioid stewardship.
  • Evidence supporting routine UDS in palliative populations requires critical evaluation.

Purpose of the Study:

  • To assess the evidence for routine UDS in palliative and cancer pain populations.
  • Examined safety benefits, cost, ethics, guideline consistency, harms, and racial disparities.

Main Methods:

  • Conducted a narrative review and critical analysis using the SANRA framework.
  • Searched PubMed/MEDLINE and systematically reviewed clinical practice guidelines (NCCN, ASCO, CDC).
  • Included studies on UDT utilization, outcomes, or policy in adult cancer or palliative care patients on opioid therapy.

Main Results:

  • No studies show routine UDS improves patient safety outcomes (e.g., overdose prevention, pain control).
  • Aberrancy rates (15-54%) reflect surveillance, not safety endpoints; UDS rarely alters opioid management.
  • Documented risks include financial toxicity, stigmatization, care termination, and racial disparities.

Conclusions:

  • Routine UDS in palliative care lacks demonstrated benefit and has documented harms.
  • Recommendations should be individualized, awaiting evidence of patient safety benefit.
  • Proposes future research and an equity-informed framework for selective screening.